Showing 11-20 of 30 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Providing blood glucose monitoring, HbA1c testing, and other in-country support to centers enrolled in the Life for a Child Program | Diabetes Australia (fka Diabetes New South Wales) | Graham Ogle | Transportfolio | 01-March-2025 to 30-September-2026 | $1,266,667.00 |
| Targeted regulatory T cells to treat type 1 diabetes | Monash University | Joshua Ooi | Cures | 01-February-2023 to 31-January-2026 | $510,000.00 |
| α-MSH/MC5R axis as an adjunctive therapeutic target for type 1 diabetes | Monash University | Michael Cowley | Improving Lives | 01-August-2019 to 30-September-2025 | $716,962.40 |
| Engineering an artificial pancreas in the gut for the treatment of diabetes | Monash University | Rong Xu | Improving Lives | 01-September-2025 to 31-August-2028 | $285,000.00 |
| A synergistic approach to preventing islet allograft rejection in beta cell replacement therapy | St. Vincent’s Institute of Medical Research | Seigmund Lai | Cures | 01-March-2025 to 29-February-2028 | $256,285.00 |
| Monitoring CD4+ T-cell responses in T1D, MS and SLE | St. Vincent’s Institute of Medical Research | Stuart Mannering | Cures | 01-September-2025 to 31-August-2026 | $149,998.36 |
| Harnessing T cell exhaustion for type 1 diabetes prevention | St. Vincent’s Institute of Medical Research | Thomas Kay | Cures | 01-November-2023 to 31-October-2026 | $2,250,000.00 |
| Improving Glucose Levels while Preventing Ketoacidosis in People with Type 1 Diabetes Receiving SGLT1/2 inhibitor Therapy Using a Novel Continuous Ketone Sensor (PARTNER) | The University of Melbourne | David O’Neal | Improving Lives | 01-November-2024 to 31-October-2026 | $221,126.00 |
| Understanding RAGE Expression and Function in Human T and Dendritic Cells to Refine the Use of RAGE Targeting Therapeutics for Type 1 Diabetes Prevention. | The University of Queensland | Josephine Forbes | Cures | 01-April-2024 to 31-March-2026 | $200,000.00 |
| FAME-1 Eye Trial Completion | The University of Sydney | Alicia Jenkins | Improving Lives | 01-July-2025 to 30-June-2028 | $545,454.35 |